Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

Inclusion Criteria

• •Patients should have a life expectancy of at least 10 years, excluding their diagnosis of breast cancer; (comorbid conditions should be taken into consideration, but not the diagnosis of breast cancer)
• •Women of reproductive potential must agree to use an effective non-hormonal method of contraception during study therapy (chemotherapy, trastuzumab, pertuzumab, and estrogen deprivation therapy) and for at least 7 months after the last dose of study therapy
• •Submission of tumor samples is required for all patients; the local pathology department policy regarding release of tumor samples must be considered in the screening process; patients whose tumor samples are located in a pathology department that by policy will not submit any samples for research purposes should not be approached for participation in the B-52 trial
• •The patient must have signed and dated an Institutional Review Board (IRB)-approved consent form that conforms to federal and institutional guidelines
• •The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• •Clinical staging for the primary tumor can be cT1c (must be 2.0 cm) or T2-T4 if clinically node negative; if the regional lymph nodes are cN1 and cytologically or histologically positive or if cN2-N3 with or without a biopsy, the primary breast tumor can be cT0-T4
• •The diagnosis of invasive adenocarcinoma of the breast must have been made by core needle biopsy
• •Ipsilateral axillary lymph nodes must be evaluated by imaging (mammogram, ultrasound, and/or magnetic resonance imaging \[MRI\]) within 6 weeks prior to randomization; if suspicious or abnormal, fine needle aspirate (FNA) or core biopsy is recommended, also within 6 weeks prior to randomization; findings of these evaluations will be used to determine the nodal status prior to randomization:
• •* Nodal status - negative
• •* Imaging of the axilla is negative
• •* Imaging is suspicious or abnormal but the FNA or core biopsy of the questionable node(s) on imaging is negative
• •* Nodal status - positive
• •* FNA or core biopsy of the node(s) is cytologically or histologically suspicious or positive
• •* Imaging is suspicious or abnormal but FNA or core biopsy was not performed
• •Patients may be premenopausal or postmenopausal at the time of randomization; for study purposes, postmenopausal is defined as:
• •* Age 56 or older with no spontaneous menses for at least 12 months prior to study entry; or
• •* Age 55 or younger with no spontaneous menses for at least 12 months prior to study entry (e.g., spontaneous or secondary to hysterectomy) and with a documented estradiol level in the postmenopausal range according to local institutional/laboratory standard; or
• •* Documented bilateral oophorectomy
• •The tumor must have been determined to be HER2-postive as follows:
• •* Immunohistochemistry (IHC) 3+ or
• •* In situ hybridization (ISH)-positive (defined by ratio of HER2 to circulating endothelial progenitors \[CEP\]17 \>= 2.0 or HER2 gene copy number \>= 6 per nucleus)
• •The tumor must have been determined to be estrogen receptor (ER) and/or progesterone (PgR) positive assessed by current American Society of Clinical Oncology (ASCO)/College of American Pathologist (CAP) guideline recommendations for hormone receptor testing; patients with \>= 1% ER or PgR staining by IHC are considered positive
• •Absolute neutrophil count (ANC) must be \>= 1200/mm\^3
• •Platelet count must be \>= 100,000/mm\^3
• •Hemoglobin must be \>= 10 g/dL
• •Total bilirubin must be =\< upper limit of normal (ULN) for the lab unless the patient has a bilirubin elevation \> ULN to 1.5 x ULN due to Gilbert's disease or similar syndrome involving slow conjugation of bilirubin
• •Alkaline phosphatase must be =\< 2.5 x ULN for the lab
• •Aspartate aminotransferase (AST) must be =\< 1.5 x ULN for the lab
• •Alkaline phosphatase and AST may not both be \> the ULN; for example, if the alkaline phosphatase is \> the ULN but =\< 2.5 x ULN, the AST must be =\< the ULN; if the AST is \> the ULN but =\< 1.5 x ULN, the alkaline phosphatase must be =\< ULN; Note: If alanine aminotransferase (ALT) is performed instead of AST (per institution's standard practice), the ALT value must be =\< 1.5 x ULN; if both were performed, the AST must be =\< 1.5 x ULN
• •Patients with AST or alkaline phosphatase \> ULN are eligible for inclusion in the study if liver imaging (computed tomography \[CT\], MRI, positron emission tomography \[PET\]-CT, or PET scan) performed within 6 weeks prior to randomization does not demonstrate metastatic disease and the requirements are met
• •Patients with alkaline phosphatase that is \> ULN but =\< 2.5 x ULN or unexplained bone pain are eligible for inclusion in the study if a bone scan, PET-CT scan, or PET scan performed within 6 weeks prior to randomization does not demonstrate metastatic disease
• •Within 6 weeks prior to randomization, the most recent serum creatinine must be =\< ULN or measured or calculated creatinine clearance must be \> 60 mL/min
• •Left ventricular ejection fraction (LVEF) assessment must be performed within 90 days prior to randomization; (LVEF assessment performed by 2-dimensional \[2-D\] echocardiogram is preferred; however, multi gated acquisition scan \[MUGA\] scan may be substituted based on institutional preferences); the LVEF must be \>= 50% regardless of the cardiac imaging facility's lower limit of normal; note: since the pre-entry LVEF serves as the baseline for comparing subsequent LVEF assessments, it is critical that this baseline study be an accurate assessment; if the baseline LVEF is \> 65%, the investigator is encouraged to have the accuracy of the initial LVEF result confirmed and repeat the test if the accuracy is uncertain
• •History of non-breast malignancies (except for in situ cancers treated only by local excision and basal cell and squamous cell carcinomas of the skin) within 5 years prior to randomization
• •Cardiac disease (history of and/or active disease) that would preclude the use of the drugs included in the treatment regimens; this includes but is not confined to:
• •* Active cardiac disease:
• •* Angina pectoris that requires the use of anti-anginal medication;
• •* Ventricular arrhythmias except for benign premature ventricular contractions;
• •* Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication;
• •* Conduction abnormality requiring a pacemaker;
• •* Valvular disease with documented compromise in cardiac function; and
• •* Symptomatic pericarditis
• •* History of cardiac disease:
• •* Myocardial infarction documented by elevated cardiac enzymes or persistent regional wall abnormalities on assessment of left ventricular (LV) function;
• •* History of documented congestive heart failure (CHF); and
• •* Documented cardiomyopathy
• •Active hepatitis B or hepatitis C with abnormal liver function tests
• •Intrinsic lung disease resulting in dyspnea
• •Poorly controlled diabetes mellitus
• •Active infection or chronic infection requiring chronic suppressive antibiotics